Anavex Life Sciences Corp (AVXL)

[RedShoulder]

So, Anavex takes its data from 450+ participants and presents it to the fda. In the data, blarcamesine is show to improve cognitive performance, but does not clear amyloid as amyloid is waste and blarcamesine stops waste, but it doesn’t clear. These results put fda in a dilemma: no amyloid removal, but cognition. The current AD staff at the fda decides, that since amyloid removal is more important than cognitive improvement (on which its previous decisions were based), that Anavex needs to perform another larger P3 trial to determine whether amyloid may be removed and/or more data to ensure cognitive improvement is achieved throughout the participants population and/or any other outlandish reason it concocts.

I don't agree with this part of the post, FDA is not going to overlook cognitive improvement in favor of reducing amyloid plaques, which is already sporting a black eye from professionals in the medical community.

Futhermore A2-73 Blarcamesine works upstream to clear out the plaques too.